Central and cerebral haemodynamic changes after antihypertensive therapy in ischaemic stroke patients: A double-blind randomised trial

Abstract Central and cerebral haemodynamic parameters can vary under similar brachial blood pressure (BP). We aimed to investigate the effects of antihypertensive agents on central and cerebral haemodynamic parameters in hypertensive patients with ischaemic stroke. The Fimasartan, Atenolol, and Vals...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mun Hee Choi, Jin Soo Lee, Sung Eun Lee, Seong-Joon Lee, Dukyong Yoon, Rae Woong Park, Ji Man Hong
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/454895e6db8b4392aa273ec94ca82585
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:454895e6db8b4392aa273ec94ca82585
record_format	dspace
spelling	oai:doaj.org-article:454895e6db8b4392aa273ec94ca825852021-12-02T15:08:49ZCentral and cerebral haemodynamic changes after antihypertensive therapy in ischaemic stroke patients: A double-blind randomised trial10.1038/s41598-018-19998-42045-2322https://doaj.org/article/454895e6db8b4392aa273ec94ca825852018-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-018-19998-4https://doaj.org/toc/2045-2322Abstract Central and cerebral haemodynamic parameters can vary under similar brachial blood pressure (BP). We aimed to investigate the effects of antihypertensive agents on central and cerebral haemodynamic parameters in hypertensive patients with ischaemic stroke. The Fimasartan, Atenolol, and Valsartan On haemodynamic paRameters (FAVOR) study was conducted in a prospective, double-blinded manner. One hundred five patients were randomly administered atenolol, valsartan, or fimasartan during 12 weeks. We measured brachial, central, cerebral haemodynamic parameters and plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) levels at baseline and after 12-week. Baseline haemodynamic parameters were balanced among the three groups. Even with similar brachial BP reduction, significantly lower central systolic BP (atenolol; 146.5 ± 18.8 vs. valsartan; 133.5 ± 20.7 vs. fimasartan; 133.6 ± 19.8 mmHg, p = 0.017) and augmentation index values (89.8 ± 13.2 vs. 80.6 ± 9.2 vs. 79.2 ± 11.6%; p = 0.001) were seen in the angiotensin receptor blockers (ARBs) groups. The pulsatility index on transcranial Doppler was significantly reduced in valsartan (p = 0.002) and fimasartan group (p = 0.008). Plasma NT-proBNP level was also significantly decreased in ARB groups, especially for the fimasartan group (37.8 ± 50.6 vs. 29.2 ± 36.9 vs.19.2 ± 27.8 pg/mL; p = 0.006). These findings suggest that short-term ARB administration would be favourable for ischaemic stroke patients with hypertension, permitting effective reduction of central pressure and dampening of cerebral pulsatility.Mun Hee ChoiJin Soo LeeSung Eun LeeSeong-Joon LeeDukyong YoonRae Woong ParkJi Man HongNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 8, Iss 1, Pp 1-8 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Mun Hee Choi Jin Soo Lee Sung Eun Lee Seong-Joon Lee Dukyong Yoon Rae Woong Park Ji Man Hong Central and cerebral haemodynamic changes after antihypertensive therapy in ischaemic stroke patients: A double-blind randomised trial
description	Abstract Central and cerebral haemodynamic parameters can vary under similar brachial blood pressure (BP). We aimed to investigate the effects of antihypertensive agents on central and cerebral haemodynamic parameters in hypertensive patients with ischaemic stroke. The Fimasartan, Atenolol, and Valsartan On haemodynamic paRameters (FAVOR) study was conducted in a prospective, double-blinded manner. One hundred five patients were randomly administered atenolol, valsartan, or fimasartan during 12 weeks. We measured brachial, central, cerebral haemodynamic parameters and plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) levels at baseline and after 12-week. Baseline haemodynamic parameters were balanced among the three groups. Even with similar brachial BP reduction, significantly lower central systolic BP (atenolol; 146.5 ± 18.8 vs. valsartan; 133.5 ± 20.7 vs. fimasartan; 133.6 ± 19.8 mmHg, p = 0.017) and augmentation index values (89.8 ± 13.2 vs. 80.6 ± 9.2 vs. 79.2 ± 11.6%; p = 0.001) were seen in the angiotensin receptor blockers (ARBs) groups. The pulsatility index on transcranial Doppler was significantly reduced in valsartan (p = 0.002) and fimasartan group (p = 0.008). Plasma NT-proBNP level was also significantly decreased in ARB groups, especially for the fimasartan group (37.8 ± 50.6 vs. 29.2 ± 36.9 vs.19.2 ± 27.8 pg/mL; p = 0.006). These findings suggest that short-term ARB administration would be favourable for ischaemic stroke patients with hypertension, permitting effective reduction of central pressure and dampening of cerebral pulsatility.
format	article
author	Mun Hee Choi Jin Soo Lee Sung Eun Lee Seong-Joon Lee Dukyong Yoon Rae Woong Park Ji Man Hong
author_facet	Mun Hee Choi Jin Soo Lee Sung Eun Lee Seong-Joon Lee Dukyong Yoon Rae Woong Park Ji Man Hong
author_sort	Mun Hee Choi
title	Central and cerebral haemodynamic changes after antihypertensive therapy in ischaemic stroke patients: A double-blind randomised trial
title_short	Central and cerebral haemodynamic changes after antihypertensive therapy in ischaemic stroke patients: A double-blind randomised trial
title_full	Central and cerebral haemodynamic changes after antihypertensive therapy in ischaemic stroke patients: A double-blind randomised trial
title_fullStr	Central and cerebral haemodynamic changes after antihypertensive therapy in ischaemic stroke patients: A double-blind randomised trial
title_full_unstemmed	Central and cerebral haemodynamic changes after antihypertensive therapy in ischaemic stroke patients: A double-blind randomised trial
title_sort	central and cerebral haemodynamic changes after antihypertensive therapy in ischaemic stroke patients: a double-blind randomised trial
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/454895e6db8b4392aa273ec94ca82585
work_keys_str_mv	AT munheechoi centralandcerebralhaemodynamicchangesafterantihypertensivetherapyinischaemicstrokepatientsadoubleblindrandomisedtrial AT jinsoolee centralandcerebralhaemodynamicchangesafterantihypertensivetherapyinischaemicstrokepatientsadoubleblindrandomisedtrial AT sungeunlee centralandcerebralhaemodynamicchangesafterantihypertensivetherapyinischaemicstrokepatientsadoubleblindrandomisedtrial AT seongjoonlee centralandcerebralhaemodynamicchangesafterantihypertensivetherapyinischaemicstrokepatientsadoubleblindrandomisedtrial AT dukyongyoon centralandcerebralhaemodynamicchangesafterantihypertensivetherapyinischaemicstrokepatientsadoubleblindrandomisedtrial AT raewoongpark centralandcerebralhaemodynamicchangesafterantihypertensivetherapyinischaemicstrokepatientsadoubleblindrandomisedtrial AT jimanhong centralandcerebralhaemodynamicchangesafterantihypertensivetherapyinischaemicstrokepatientsadoubleblindrandomisedtrial
_version_	1718387994462781440

Central and cerebral haemodynamic changes after antihypertensive therapy in ischaemic stroke patients: A double-blind randomised trial

Ejemplares similares